STOCK TITAN

OptimizeRx Sets First Quarter 2023 Conference Call for May 10, 2023at 4:30 p.m. ET

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

OptimizeRx Corp (Nasdaq: OPRX) will hold a conference call on May 10, 2023, at 4:30 p.m. Eastern Time to discuss its first-quarter results for the period ending March 31, 2023. The financial results will be released prior to the call. Interested parties can join via a toll-free number at 1-888-886-7786 or internationally at 1-416-764-8658, using conference ID 54210852. The call will also be accessible through a webcast. A replay will be available for 12 months on OptimizeRx’s investor website. OptimizeRx focuses on providing technology solutions that improve patient engagement and ensure adherence to therapies.

Positive
  • Scheduled earnings call indicates transparency and ongoing communication with investors.
  • Focus on technology solutions suggests potential for growth in patient engagement and adherence.
Negative
  • None.

ROCHESTER, Mich., April 26, 2023 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy will hold a conference call on Wednesday, May 10, 2023 at 4:30 p.m. Eastern Time to discuss its results for the first quarter ended March 31, 2023. The financial results will be issued in a press release prior to the call.

OptimizeRx management will host the call, followed by a question-and-answer period. Details for the conference call can be found below:

Date:Wednesday, May 10, 2023
Time:4:30 p.m. Eastern time (1:30 p.m. Pacific time)
Toll Free:1-888-886-7786
International:1-416-764-8658 
Conference ID:54210852
Call Me Link:https://emportal.ink/41EWFJO
Webcast:https://viavid.webcasts.com/starthere.jsp?ei=1612255&tp_key=f4c15a1272

Please call the conference telephone number or log on to the web access link five minutes prior to the start time.

A replay of the call will remain available for 12 months via the Investors section of the OptimizeRx website at www.optimizerx.com/investors.  

About OptimizeRx
OptimizeRx provides best-in-class health technology that enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. Connecting over 60% of U.S. healthcare providers and millions of their patients through an intelligent technology platform embedded within a proprietary digital point-of-care network, OptimizeRx helps patients start and stay on their medications. 

For more information, follow the Company on TwitterLinkedIn or visit www.optimizerx.com

Important Cautions Regarding Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates”, “believes”, “estimates”, “expects”, “forecasts”, “intends”, “plans”, “projects”, “targets”, “designed”, “could”, “may”, “should”, “will” or other similar words and expressions are intended to identify these forward-looking statements. All statements that reflect the Company’s expectations, assumptions, projections, beliefs or opinions about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements relating to the Company’s growth, business plans and future performance. These forward-looking statements are based on the Company’s current expectations and assumptions regarding the Company’s business, the economy, and other future conditions. The Company disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise, except as required by applicable law. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition, and other risks summarized in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, its subsequent Quarterly Reports on Form 10-Q, and its other filings with the Securities and Exchange Commission.

OptimizeRx Contact 
Andy D’Silva, SVP Corporate Finance
adsilva@optimizerx.com

Media Relations Contact 
Kimberley Sirk, Media Relations Manager
ksirk@optimizerx.com

Investor Relations Contact
Ashley Robinson
LifeSci Advisors, LLC
arr@lifesciadvisors.com


FAQ

When is the OptimizeRx Q1 2023 earnings call?

The earnings call is scheduled for May 10, 2023, at 4:30 p.m. Eastern Time.

How can I participate in the OptimizeRx earnings call?

You can participate by calling 1-888-886-7786 toll-free or 1-416-764-8658 internationally, using conference ID 54210852.

Where can I find the OptimizeRx Q1 2023 financial results?

The financial results will be issued in a press release prior to the earnings call on May 10, 2023.

Is there a way to access the OptimizeRx earnings call after it ends?

Yes, a replay of the call will be available for 12 months on the OptimizeRx investor website.

What is the purpose of the OptimizeRx earnings call?

The earnings call aims to discuss the company's financial results for the first quarter ending March 31, 2023.

OptimizeRx Corporation

NASDAQ:OPRX

OPRX Rankings

OPRX Latest News

OPRX Stock Data

103.16M
15.73M
14.23%
68.94%
5.96%
Health Information Services
Services-business Services, Nec
Link
United States of America
WALTHAM